# Clinical attachment loss in the use of adjunctive antimicrobial photodynamic therapy in Stages II-IV Grade C molar-incisor periodontitis: A systematic review and meta-analysis

## Zahra Baghani<sup>1\*</sup>, Samira Basir Shabestari<sup>2</sup>, Malihe Karrabi<sup>3</sup>

# ABSTRACT

This systematic review and meta-analysis aimed to assess the extent of clinical attachment loss (CAL) as a clinical parameter in the efficacy of antimicrobial photodynamic therapy (aPDT) in non-surgical management of Stages II-IV Grade C molar-incisor pattern periodontitis. This review protocol was conducted in accordance with Preferred Reporting Items for Systematic Reviews and Meta-Analysis statements and is registered in PROSPERO (CRD42022321211). An electronic and manual search was conducted for relevant articles comparing the efficacy of aPDT versus scaling and root planning (SRP) alone or with amoxicillin/metronidazole (AMX/MET) published up until December 2021. The mean CAL, probing depth reduction, and BOP with a 95% confidence interval were pooled and compared between the two groups with CAL < and > 7 mm using a random-effect model after 3 and 6 months. To assess the heterogeneity of the findings, the I2 test was applied, and publication bias was evaluated by visual examination of the funnel plot symmetry. Analysis of nine studies indicated a significant difference in clinical attachment gain in patients with CAL > 7 mm between the aPDT group and the SRP alone (mean difference = 0.92, 95% CI = 0.01-1.84, p = 0.05) and SRP + AMX/MET (mean difference = 0.91, 95% CI = -0.14-1.68, p = 0.02) control groups. However, this difference was not significant in patients with CAL < 7 mm. Despite the limitations of the included studies, aPDT can be suggested to improve clinical parameters in Grade C molar-incisor pattern periodontitis with CAL > 7 mm. However, its application in milder cases requires further investigation.

KEYWORDS: Aggressive periodontitis, attachment loss, photo chemotherapy, periodontal debridement, dental scaling, therapy.

# INTRODUCTION

Aggressive periodontitis (AgP) is an inflammatory disease characterized by rapid alveolar bone destruction and extensive clinical attachment loss (CAL) that occurs in response to polymicrobial factors and can be mild, moderate, or severe [1,2]. Although in the last world workshop on the classification of periodontal and peri-implant diseases, severity (Stages I-IV) or complexity and speed of progression were the basis of the new classification, Grade *C* represents the rapid

Submitted: 08 March 2022/Accepted: 02 May 2022/ Published online: 29 May 2022

Funding: The authors received no specific funding for this work.



©The Author(s) (2022). This work is licensed under a Creative Commons Attribution 4.0 International License rate of progression [3]. The speed of disease progression and the complications of management are due to the self-limiting nature of this disease and the impaired innate immunity [4]. Thus, AgP is different from chronic periodontitis (CP), and it is better assessed separately. The provision of prompt and efficient treatment with no side effects and long-term maintenance of the results are the challenges clinicians encounter in managing patients with AgP to prevent early tooth loss in young patients [5].

Non-surgical periodontal therapy is the treatment protocol primarily suggested in the management of AgP to transiently eliminate or decrease the count of microorganisms and improve the clinical parameters [6,7]. Systemic or local antibiotic therapy is another treatment the modality for the treatment of periodontitis. Despite the positive clinical results, this modality did not gain wide acceptance due to shortcomings such as the risk of antibiotic resistance, side effects of antibiotic therapy [8], difficult manipulation, risk of displacement in topical application, and the need for high patient cooperation [9]. Considering the drawbacks of the above-mentioned two modalities, antimicrobial photodynamic therapy (aPDT) was introduced as a novel alternative with the same advantages and no serious complications as an adjunct to mechanical treatments for periodontitis [10,11]. In aPDT, the chemical

<sup>&</sup>lt;sup>1</sup>Department of Periodontics, Faculty of Dentistry, Sabzevar University of Medical Sciences, Sabzevar, Iran,

<sup>&</sup>lt;sup>2</sup>Department of Oral Medicine, Firoozgar Hospital, Iran University of Medical Sciences, Tehran, Iran,

<sup>&</sup>lt;sup>3</sup>Department of Periodontics, Faculty of Dentistry, Sabzevar University of Medical Sciences, Sabzevar, Iran

<sup>\*</sup>Corresponding author: Zahra Baghani, Department of Periodontics, Faculty of Dentistry, Sabzevar University of Medical Sciences, Sabzevar, Iran. E-mail: za\_baghani@yahoo.com

DOI: https://doi.org/10.17305/bjbms.2022.7157

Conflict of interests: The authors declare no conflict of interests.

molecules of the photosensitizer are stimulated by a light source with a wavelength compatible with the absorption spectrum of the photosensitizer and produce reactive oxygen species. Such reactive species cause antibacterial reactions in more classes of microorganisms such as Gram-positive and Gram-negative bacteria [12], fungi [13], and viruses [14], which are safe, more acceptable as non-surgical methods of treatment, not toxic to the human tissues, and cannot cause bacterial resistance either [15-17]. Although according to the Specific Plaque theory (1977) [18], the oral disease could be initiated by a number of specific pathogens, Keystone theory (2012) [19] indicates that certain low-abundance microbial pathogens can cause inflammatory disease by increasing the quantity of the normal microbiota and by changing its composition. Therefore, it seems that the composition of the normal flora around bacterial niches of microorganisms that are affected by aPDT is not normal.

Extensive clinical studies on humans have reported the positive effect of aPDT on clinical parameters such as CAL, PPD, and bleeding on probing (BOP) and immunological parameters in patients with AgP compared with scaling and root planning (SRP). A reduction of orange and red complex species of microorganism and significantly lower mean levels of IL-1 $\beta$  in deep periodontal pockets were observed at a 3-month follow-up [20-24]. However, some studies could not confirm these effects with a high level of certainty [10,25,26]. On the other hand, some research has not definitively indicated positive effects of aPDT in comparison to SRP or AMX/ MET. Thus, a conclusive result regarding the application of a PDT for the treatment of AgP has not been reached. One reason for not reaching a definite conclusion in this respect is the existing controversy regarding the effects of parameters such as frequency of aPDT sessions, type of photosensitizer, the effective energy density per square centimeter, and the efficacy of a PDT based on disease severity, which should be further elucidated. To achieve a reliable conclusion regarding the application of aPDT, several meta-analyses[24,27,28] evaluated the efficacy of a PDT along with SRP for the treatment of AgP and showed its comparable clinical efficacy to SRP + amoxicillin-metronidazole (AMX/MET). However, when compared with SRP alone, aPDT only caused significant improvement in deep pockets. However, limitations such as high variability in aPDT variables such as voltage, wavelength, and type of photosensitizer, and heterogeneity across the studies did not allow the study to reach a definite and reliable conclusion. A recent meta-analysis [28] on this topic evaluated five randomized clinical trials (RCTs) on the effect of aPDT on clinical parameters such as pocket depth, CAL, and bleeding on probing (BOP) compared with antibiotic therapy with AMX/MET after SRP in periodontitis patients. Despite the limitations of included studies and the high heterogeneity

of the findings, the results indicated comparable efficacy of aPDT with systemic antibiotic therapy with AMX/MET in combination with mechanical debridement.

Overall, not assessing the effect of aPDT based on disease severity and evaluation of both AgP and CP as one entity (periodontitis) [28,29] can cause under- or over-treatment. Moreover, active disease parameters such as BOP and plaque score reflect the presence of active disease and the patient's ability to perform proper plaque control and no severity of the disease. Hence, the CAL parameter is selected to estimate the extent of periodontal disease and destruction of the periodontium. Therefore, this systematic review and meta-analysis aimed to assess the effect of adjunctive aPDT on Stages II-IV Grade *C* molar-incisor pattern periodontitis patients with CAL < 7 mm and > 7 mm to prevent under- or over-treatment.

## MATERIALS AND METHODS

#### PICO protocol and search strategy

This systematic review was conducted in accordance with the Preferred Reporting Items for Systematic Reviews and Meta-Analysis (PRISMA) Statement guidelines and Cochrane Collaboration recommendations. The systematic review protocol was registered in the Prospective Register of Systematic Reviews (PROSPERO); ref CRD 42022321211. The PICO components were as follows:

- Population: Patients diagnosed with Stages II-IV Grade C molar-incisor pattern periodontitis
- Intervention: aPDT along with SRP
- Comparison: SRP alone or along with antibiotic therapy with AMX/MET
- Outcome: CAL, PD, clinical attachment gain, and BOP
- Focused question: Can the extent of CAL affect the efficacy of aPDT as an adjunct to SRP or AMX/MET in Stages II-IV Grade C molar-incisor pattern periodontitis patients?

#### Search strategy

The keywords were selected according to MeSH to determine the search strategy. The search algorithm was as follows:

"Early-Onset Periodontitis" [MeSH] OR "Juvenile Periodontitis" [MeSH] OR "Aggressive Periodontitis" [MeSH] OR "Periodontal disease" OR Periodontitis [MeSH] OR "Periodontal pockets" [MeSH] OR "Alveolar bone loss" OR "Attachment loss"

AND

"Non-surgical therapy" OR "Photochemotherapy" [MeSH] OR "Photodynamic therapy"

AND

"Scaling Root planing" OR "Dental Scaling" [MeSH] OR "Dental Root planing" OR "Periodontal debridement" [MeSH] The keywords were searched electronically in Cochrane, Medline, and EMBASE databases and manually in the following journals: Journal of Periodontology, Journal of Clinical Periodontology, Journal of Periodontal Research, Laser in Medical Science, Periodontology 2000, and Photo diagnosis and Photodynamic Therapy.

A title/abstract search was conducted from the first record up until December 2021. The search was conducted by two blinded reviewers (ZB and SB), and inter-reviewer reliability analysis was also conducted [30]. The screening of titles/ abstracts was performed to find eligible studies. The disagreements between the reviewers regarding the inclusion criteria were resolved by discussing a third reviewer (MK). Next, the full text of the eligible articles was read. Figure 1 shows the PRISMA flow diagram of the screening process.

## Eligibility criteria

#### Inclusion criteria

Studies that met the following inclusion criteria were included in the meta-analysis:

- Stages II-IV Grade C molar-incisor pattern periodontitis patients who met the 2017 diagnostic criteria for periodontal disease or AgP patients according to 1999 diagnostic criteria of periodontal disease
- Parallel or split-mouth RCTs
- Studies with a control group of SRP alone or SRP combined with antibiotic therapy with AMX/MET
- A PDT + SRP as the intervention group
- Assessment of CAL and PD
- Reporting the mean and standard deviation of the variables
- Minimum follow-up of 3 months
- No limitation with respect to the type of photosensitizer, voltage, or wavelength of light
- English articles.

#### Exclusion criteria

- Assessment of the efficacy of aPDT for the treatment of CP or studies that did not differentiate between AgP and CP patient
- In vitro studies
- Case reports, case series, systematic reviews, unpublished articles, letters to editors, and abstracts
- Presence of systemic diseases
- Smoker patients.

## Data extraction

After reading the full text of the articles, the review, quality assessment, and data extraction were performed by two independent reviewers. The second author (ZB) confirmed the accuracy of the extracted data, and the ambiguities were discussed with the third author (MK) until a consensus was reached. The extracted data included the first author's name, country, age, gender and number of patients, follow-up time, laser parameters (voltage and wavelength), type of photosensitizer, frequency of treatment sessions, CAL, PD, and BOP parameters (as mean and standard deviation), and dosage, and duration of antibiotic therapy.

## Risk of bias (RoB)

According to the Cochrane Handbook for Systematic Reviews of Interventions, the Revised Cochrane RoB tool for randomized trials, version 2.0 (RoB 2) for each included study was independently assessed as follows by two of the authors (ZB and SB): This analysis was evaluated under the following headings:

- 1. Bias arising from the randomization process
- 2. Bias due to deviations from intended interventions
- 3. Bias due to missing outcome data
- 4. Bias in measurement of the outcome
- 5. Bias in the selection of the reported result.

The risk of bias was categorized as low, some concerns and high. Disagreements between the reviewers were resolved by consultation with a third author (MK).

## Data synthesis

Details of the studies extracted independently by the two reviewers (ZB and SB) were as follows: Age, gender, number of patients, diagnostic criteria for periodontitis, type of intervention, type of photosensitizer, laser parameters (wavelength, power, duration of radiation, and energy density), follow-up time, and clinical parameters (CAL, PD, and BOP). The extracted clinical findings included PD, CAL, and BOP in millimeters (mm) which were reported as mean and standard deviation, and were tabulated. Data were entered into RevMan version 5.0. The missing data necessitating contact with the corresponding author did not exist in any study.

## Meta-analysis

Some recent achievements indicated aPDT promotes additional positive clinical effects in deep pockets and attachment loss > 7 mm of Grade C, Stages III-IV periodontitis [20,23]. It seems attachment loss > 7 mm can be used as a classification basis. Thus, due to no evaluation of different stages of disease in RCTs, the included studies were categorized into two groups, with CAL < 7 mm and CAL > 7 mm. The effect of treatment was reported as a mean difference with a 95% confidence interval (CI). Furthermore, in some studies, SRP was performed along with antibiotic therapy for the control group. Hence, in order to increase the accuracy of the results, within-group analysis was also conducted in SRP + antibiotic therapy group and SRP alone at 3- and 6-month follow-ups. The random-effect model



FIGURE 1. Flowchart of the search strategy. SRP: Scaling Root planning, AMX/MET: Amoxicillin/ Metronidazole.

of RevMan version 5 was also used for data analysis at P < 0.05 level of significance. To detect statistical heterogeneity, forest plots were visually inspected through the presence of outlier studies. For the assessment of findings heterogeneity, the I2 test was applied in a range of 0-100% with the following explanation; 0% = no evidence of heterogeneity; 30-60% = moderate heterogeneity; and 75-100% = high heterogeneity [31]. To assess the outcomes after the negation of heterogeneous studies, a sensitivity analysis was performed [32]. Furthermore, the publication bias was analyzed by visual assessment of funnel plot symmetry [33].

## RESULTS

## Selection of studies

Figure 1 shows the PRISMA flow diagram of study selection. An electronic search of Cochrane (120), Medline (363), and EMBASE (169) databases yielded 656 articles. Hand searching of six journals published in 2021 yielded four more articles [31-34]. After removing 155 duplicated articles, 501 articles remained. Screening based on titles and abstracts yielded 17 articles that met the inclusion criteria and underwent full-text analysis (inter-reviewer agreement kappa = 0.84). The full-text assessment revealed that nine articles were accepted to include in this systematic review and analysis [10,20-23,25,26,35,36]. Thus, eight articles could not undergo meta-analysis (inter-reviewer agreement kappa = 1) because three articles [27,37,38] evaluated AgP and CP cases altogether, and two other studies [39,40] only evaluated CP patients. Three other RCTs were excluded due to not assessing the clinical parameters, having a control group not meeting the inclusion criteria, or being a review article (Appendix S1) [41-43]. Eventually, the data of nine articles were extracted and underwent qualitative and quantitative analyses by the software.

## General characteristics of the included studies

In this study, nine RCTs conducted in Iran [26], Saudi Arabia [20], Poland [35,36], Brazil [10,23,25], Turkey [22], and India [21] were evaluated (Table 1). Arwailer et al. [36], 2012, reported clinical parameters after a 3-month follow-up and then reported their findings at the 6-month follow-up in another study conducted in 2014 [35]. The number of enrolled patients ranged from a minimum of 9 to a maximum of 24, with a mean age of 27.5-37.4 years. The mean female/male percentage was 5.8-71%. All nine included studies only evaluated AgP patients. The test group of studies received aPDT following non-surgical mechanical debridement (SRP). The control group received SRP alone or along with antibiotic therapy with AMX/MET. SRP was conducted with an ultrasonic scaler [20,21,26] in some studies while hand instruments were also used in addition to an ultrasonic scaler in some other studies [22,23,36]. Only one RCT used hand instruments for SRP [10]. Andere et al. [25] reported that SRP should be performed until plaque index reaches below 20%. Among the studies in which the control group received SRP plus antibiotic therapy with 375 [40] to 500 mg [20] AMX and 250 [40] to 500 [20] mg MET 3 times a day for a total duration of 7 days, five studies reported the results at the 3-month follow-up [10,21-23,35,36], two studies reported the results at the 6-month follow-up [25,35], and one study [20] reported the results at both the 3- and 6-month follow-ups. The CAL reported outcomes varied from studies reporting the optimal efficacy of aPDT in AgP patients [20,21,23] to those not reporting any advantage over SRP alone [10,22,25,26]. Some others reported superior results in the group that received AMX/MET [35,36] (Table 1).

#### Laser parameters in the included studies

The diode laser parameters varied across the included studies as follows: Wavelength of 625-810 nm, irradiation time of 60-120 seconds, and laser power of 60-100 mW. The type of photosensitizer was phenothiazine chloride in four studies [10,20,23,36], toluidine blue in three studies [21,22,26], and methylene blue in one study. The optical fiber probe diameter ranged from 0.2 to 0.6 mm as mentioned in some studies [10,20,22,23]. The pre-irradiation time of the photosensitizer ranged from 1 minute [10,20,23,25,26] to 3 minutes [21,22,36]. The frequency of application of a PDT ranged from 1 to 4 times with daily or weekly intervals.

The energy density was not calculated in five studies. Only four studies report total energy (fluency per site), and its value ranged from 2.49 to 129 J/cm<sup>2</sup> [20,22,23,25].

#### Quality of clinical studies

The risk of bias was independently calculated for each study by two reviewers (SB and ZB) according to the recommendations of the CONSORT statement using the ROB-2 tool [44]. In this process, four studies that lacked one or more of the required parameters for qualitative assessment were classified as having a high risk of bias. Five other studies that had all the parameters were categorized as having a low risk of bias, as shown in Figure 2. In the included studies, random sequence generation was conducted with different methods. The majority of the included studies [22,23,25,35,36] used computer-generated random numbers while in two other studies [10,21], the test and control groups were randomly selected by a coin toss or flipping a coin. Two studies did not mention the randomization method [20,26].

Regarding the study design, five studies [20,22,25,35,36] had a parallel design and four studies [10,21,23,26] had a splitmouth design. The examiner was blinded to the group allocation of patients in all studies except one [22]. Three studies reported that the examiner who measured the clinical parameters was not involved in the process of examination and treatment of patients [10,25,26]. Three studies mentioned that group allocation was performed by a researcher not involved in the process of data collection and treatment of patients [20,23,25]. Furthermore, all variables mentioned in each study had no reporting bias in the analysis phase except for one study [36] that did not perform a 6-month follow-up and performed this analysis in the next study.

#### The main outcome of the studies

All clinical parameters evaluated in included studies indicated the positive efficacy of aPDT + SRP for reduction of PD, clinical attachment gain, and BOP [10,20-23,25,26,35,36]; although the difference with the control group (SRP alone or SRP + AMX/MET) was not significant in most studies [25,26,36]. In CAL assessment, studies that compared aPDT with SRP + AMX/MET showed comparable efficacy of aPDT and AMX/ MET therapy [20], and some others even showed that antibiotic therapy with AMX/MET was more effective than aPDT [36].

This meta-analysis included all parallel design and splitmouth RCTs and compared the efficacy of aPDT with SRP alone or in combination with AMX/MET in two groups with CAL < 7 and > 7 mm. The mean difference in attachment gain at the 3-month follow-up indicated a significant difference in patients with CAL > 7 mm between the aPDT group and both SRP alone and SRP plus AMX/MET groups; however, no significant difference in CAL gain was noted in patients with CAL < 7 mm (Figures 3 and 4). The results of CAL gain at the 6-month follow-up revealed significant differences between the groups (SRP alone/aPDT and SRP+ AMX/MET/aPDT) (Appendix S2). Furthermore, the mean difference in PD reduction after 3 months was only significant in patients with CAL > 7 mm between the aPDT group and SRP alone and SRP + AMX/MET (Figure 5). However, in comparison with SRP alone, a significant difference was noted in both CAL < 7and > 7 mm (Appendix S<sub>3</sub>). Regarding BOP, a wide variation existed among the studies in the adopted method for BOP measurement and reporting of this parameter. Resultantly, only two studies were included in this analysis, and the results indicated high heterogeneity of the studies and the absence of a significant difference among the groups (Figure 6).

Study ID	Study design/ number	Age	Male/ female	CAL (moderate≤7 mm_severe>7 mm)	Intervention groups (test-control)	Photosensitizer	Laser parameters	Follow-up	Evaluated clinical	Conclusion
De Oliveira et al., 2007, Brazil	RCT/10	$31.01 \pm 4.43$	2/8	severe	SRP (hand instruments under local anesthesia)+PDT-SRP alone	Phenothiazine chloride	Wavelength: 660 nm Power: 60 mW Time: 60 seconds	3 months	PD, CAL, GI, BOP, GR, PI	PDT and SRP showed similar clinical results in the non-surgical treatment of aggressive periodontitis
Arweiler et al., 2012, Poland	RCT/17	37.4±8.0	7/10	Moderate, severe	SRP+PDT-SRP (ultrasound instruments+hand instruments)+PDT-SRP+AMX/ MET amoxicillin=375 mg metronidazole=250 mg 3 <daily 7="" dars<="" for="" td=""><td>Phenothiazine chloride</td><td>Wavelength: 660 nm Power: 75 mW Time: 10 seconds</td><td>3 months</td><td>PD, CAL, GI, BOP, GR, PI</td><td>PDT and SRP showed similar clinical results in the non-surgical treatment of aggressive periodontitis</td></daily>	Phenothiazine chloride	Wavelength: 660 nm Power: 75 mW Time: 10 seconds	3 months	PD, CAL, GI, BOP, GR, PI	PDT and SRP showed similar clinical results in the non-surgical treatment of aggressive periodontitis
Arweiler et al, 2014, Poland	RCT/17	37.3±8.0	7/10	Moderate, severe	SRP (ultrasound instruments+hand instruments)+PDT-SRP+AMX/ MET amoxicillin=375 mg metronidazole=250 mg 3×daily for 7 days	Phenothiazine chloride	Wavelength: 660 nm Power: 60 mW Time: 60 seconds	6 months	PD, CAL, GI, BOP, GR, PI	While both treatments resulted in statistically significant clinical improvements, AB showed statistically significantly higher PD reduction
Chitsazi et al., 2014, Iran	RCT/24	29	9/15	Moderate	SRP (ultrasound instruments)+PDT-SRP alone	Toluidine blue	Wavelength: 670-690 nm Power: 75 mW Time: 2 minutes	3 months	PD, CALGI, BOP, GR	Results did not show additional benefits from PDT as an adjunctive treatment of pa-tients with aggressive periodontitis.
Moreria et al., 2015, Brazil	RCT/20	30.6±4.25	2/18	Moderate, severe	SRP (ultrasound instruments+hand instruments)+PDT-SRP alone	Phenothiazine chloride	Wavelength: 670 nm Power: 75 mW Time: 10 s	1, 3 months	PD, CAL, GR	The application of aPDT promotes additional clinical, in the treatment of deep periodontal pockets in AgP.
Annaji et al., 2016, India	R CT/15	27.5±3.71	6/9	severe	SRP (ultrasound instruments)+PDT-SRP alone	Toluidine blue-O 1 mg/ml	Wavelength: 810 nm Power: 0.1 W Time: 3 minutes	3 months	PD, CAL, PI, BOP	Photodynamic therapy is a valuable treatment modality adjunctive to conventional scaling and root planing
Andere et al., 2018, Brazil	RCT	33.11±4.26	1/17	severe	SRP (no information)+PDT-SRP alone	Methylene blue 10 mg/ml	Wavelength: 660 nm Power: 60 mW Time: 1 minute	6 months	PD, CAL, GR, BOP	aPDT may not provide benefits above and beyond those of antibiotic treatment in terms of clinical periodontal parameters
Borekci et al. 2019, Turkey	RCT	28.7±3.9	5/7	severe	SRP (ultrasound instruments+hand instruments)+PDT-SRP only	Toluidine blue O	Wavelength: 625-635 nm Power: of 1000 mW Time: 10 seconds	3 months	PD, CAL, PI, SBI	PDT as an adjunct to NPT does not lead to any beneficial effects on the investigated clinical and microbiological parameters
Al-Khureif et al., 2019, Saudi Arabia	RCT	29.61±3.2	3/6	Moderate, severe	SRP (ultrasound instruments underlocal anesthetics)+PDT-SRP+AMX/ MET amoxicillin=500 mg metronidazole=500 mg	Phenothiazine chloride	Wavelength: 670 nm Power: of 75 mW Time: 10 seconds	3,6 months	PD, CAL, PI, BOP	Test group showed a statistically significant reduction of deep periodontal pockets and gain in CAL

TABLE 1. Key characteristics of included studies

Unique ID	Study ID	Experimental	<b>Comparator</b>	Outcome	<u>D1</u>	<u>D2</u>	<u>D3</u>	<u>D4</u>	<u>D5</u>	<b>Overall</b>		
1	Al-Khurief et al. 2019	SRP+aPDT	SRP+AMX/MET	CAL	+	+	) +	.).,	• • •	+	+	Low risk
2	Bechara et al. 2018	SRP+ aPDT	SRP alone	CAL	+	+	+		+	+		Some concerns
3	Borekci et al. 2018	SRP+aPDT	SRP alone	CAL	+	!	+		+			High risk
4	Annaji et al. 2016	SRP+aPDT	SRP alone	CAL	+	+	+		+	+		
5	Chitsazi et al. 2014	SRP+ aPDT	SRP alone	CAL	C	+	ł		.) +		D1	Randomisation process
6	Moreira et al. 2014	SRP+aPDT	SRP alone	CAL	+	+	+		. +	•	D2	Deviations from the intended interventions
7	Arweiler et al. 2014	SRP+aPDT	SRP+AMX/MET	CAL	C		+		. +		D3	Missing outcome data
8	Arweiler et al.2012	SRP+aPDT	SRP+AMX/MET	CAL	C		+		. +		D4	Measurement of the outcome
9	Oliveira et al. 2007	SRP+aPDT	SRP alone	CAL	+	+			+	+	D5	Selection of the reported result
A												

#### As percentage (intention-to-treat)



В

FIGURE 2. Risk of bias summary (A) and risk of bias graph (B). SRP: Scaling Root Planning, PDT: Photodynamic therapy, CAL: Clinical Attachment Loss.

	SR	P + PD	т	SRP o	r SRP+	⊦AB		Std. Mean Difference		Std. Mean Difference
Study or Subgroup	Mean	SD	Total	Mean	SD	Total	Weight	IV, Random, 95% CI	Year	IV, Random, 95% CI
2.2.4 CAL 3 months Total										
Oliveira et al. (S) 2007	1.19	1.98	10	1.52	2.53	10	4.8%	-0.14 [-1.02, 0.74]	2007	
Arwailer et al. (M) 2012	1.1	0.67	17	1.6	0.71	18	5.3%	-0.71 [-1.39, -0.02]	2012	
Moreira et al. (S) 2014	2.77	0.5	20	1.75	0.72	20	5.2%	1.61 [0.89, 2.34]	2014	
Chitsazi et al. (M) 2014	1.29	0.62	24	0.75	0.65	24	5.6%	0.84 [0.24, 1.43]	2014	
Moreira et al. (M) 2014	1.53	0.59	20	1.58	0.63	20	5.5%	-0.08 [-0.70, 0.54]	2014	-
Annaji et al. (S) 2016	1.3	0.39	15	0.28	0.36	15	4.4%	2.64 [1.63, 3.66]	2016	
Anderea et al. (S) 2018	2.5	0.99	18	2	0.67	18	5.4%	0.58 [-0.09, 1.25]	2018	
Borekci et al. (S) 2018	0.62	0.96	12	0.59	0.94	12	5.0%	0.03 [-0.77, 0.83]	2018	
Al-Khurief et al.(S) 2019	2.7	1.13	9	1.68	1.18	8	4.4%	0.84 [-0.17, 1.84]	2019	
Al-Khurief et al.(M) 2019	2.4	1.03	9	1.68	1.07	8	4.5%	0.65 [-0.33, 1.64]	2019	
Subtotal (95% CI)			154			153	50.0%	0.60 [0.04, 1.15]		•
Heterogeneity: Tau <sup>2</sup> = 0.63	3; Chi² =	46.73,	df = 9	(P < 0.0)	0001); I	<sup>2</sup> = 819	6			
Test for overall effect: Z = 1	2.11 (P =	: 0.03)								
2.2.5 CAL 3 months AL <	7 mm									
Arwailer et al. (M) 2012	1.1	0.67	17	1.6	0.71	18	5.3%	-0.71 [-1.39, -0.02]	2012	
Chitsazi et al. (M) 2014	1.29	0.62	24	0.75	0.65	24	5.6%	0.84 [0.24, 1.43]	2014	
Moreira et al. (M) 2014	1.53	0.59	20	1.58	0.63	20	5.5%	-0.08 [-0.70, 0.54]	2014	-
Al-Khurief et al.(M) 2019	2.4	1.03	9	1.68	1.07	8	4.5%	0.65 [-0.33, 1.64]	2019	±
Subtotal (95% CI)			70			70	20.8%	0.16 [-0.56, 0.88]		-
Heterogeneity: Tau <sup>2</sup> = 0.4	); Chi <sup>2</sup> =	12.69,	df = 3	(P = 0.0)	05); I <sup>2</sup> =	76%				
Test for overall effect: Z =	0.43 (P =	: 0.67)								
226 CAL 2 months AL N	7									
Clinaina et al. (0) 2007	4.40	4 00	40	4.50	0.50	40	4.000	04414 00 0 74	2007	
Oliveira et al. (S) 2007	1.19	1.98	10	1.52	2.53	10	4.8%	-0.14 [-1.02, 0.74]	2007	
Moreira et al. (S) 2014	2.11	0.5	20	1.75	0.72	20	5.2%	1.61 [0.89, 2.34]	2014	
Annaji et al. (S) 2016	1.3	0.39	15	0.28	0.30	15	4.4%	2.04 [1.03, 3.00]	2016	
Borekci et al. (S) 2018	0.62	0.90	12	0.59	0.94	12	5.0%	0.03 [-0.77, 0.83]	2018	
Anderea et al. (S) 2018	2.5	0.99	18	1 60	0.67	18	5.4%	0.58 [-0.09, 1.25]	2018	
Subtotal (95% CI)	2.7	1.13	9	1.08	1.18	83	4.4%	0.84 [-0.17, 1.84]	2019	
Hotorogonoity Tous = 0.7	· Chiz-	25.05	df = 5	/D ~ 0 0	041-18	- 010	20.270	0.51 [0.14, 1.00]		-
Toot for overall offect: 7 -	+, CIIF =	20.85	ui = 5 i	(= ~ 0.01	JUT), F	- 01%				
rescior overall ellect. Z =	2.31 (P=	0.02)								
Total (95% CI)			308			306	100.0%	0.59 [0.21, 0.97]		◆
Heterogeneity: Tau <sup>2</sup> = 0.5	3; Chi <sup>2</sup> =	93.46.	df = 19	) (P < 0.1	00001)	; I <sup>2</sup> = 80	%			
Test for overall effect: Z =	3.07 (P =	0.002	)		.,					-4 -2 U 2 4
Test for subgroup differen	ces: Ch	<sup>2</sup> =1.9	9, df = 1	2 (P = 0.	37), I <sup>2</sup> =	= 0%				ORF U ORFTAD ORFTPUT

**FIGURE 3.** Forest plot of CAL gain at 3 months follow-up between PDT + SRP and SRP + AMX/MET groups. SRP: Scaling Root Planning, PDT: Photodynamic therapy, AL: Attachment Loss, AMX/MET: Amoxicillin/Metronidazole, CAL: Clinical Attachment Loss. \(S): Severe, (M): Moderate

	PD	T+SRF	0	SR	P alon	е		Std. Mean Difference		Std. Mean Difference
Study or Subgroup	Mean	SD	Total	Mean	SD	Total	Weight	IV, Random, 95% CI	Year	IV, Random, 95% CI
1.3.1 CAL 3 months Tota	al									
Oliveira et al. (S) 2007	1.19	1.98	10	1.52	2.53	10	6.7%	-0.14 [-1.02, 0.74]	2007	
Moreira et al. (S) 2014	2.77	0.5	20	1.75	0.72	20	7.3%	1.61 [0.89, 2.34]	2014	
Moreira et al. (M) 2014	1.53	0.59	20	1.58	0.63	20	7.7%	-0.08 [-0.70, 0.54]	2014	
Chitsazi et al. (M) 2014	1.29	0.62	24	0.75	0.65	24	7.8%	0.84 [0.24, 1.43]	2014	
Annaji et al. (S) 2016	1.3	0.39	15	0.28	0.36	15	6.1%	2.64 [1.63, 3.66]	2016	
Borekci et al. (S) 2018	0.62	0.96	12	0.59	0.94	12	7.0%	0.03 [-0.77, 0.83]	2018	
Anderea et al. (S) 2018	2.5	0.99	18	2	0.67	18	7.5%	0.58 [-0.09, 1.25]	2018	
Subtotal (95% CI)			119			119	50.0%	0.75 [0.10, 1.40]		◆
Heterogeneity: Tau <sup>2</sup> = 0.6	52; Chi <sup>2</sup> =	= 32.82	2, df = 6	(P < 0.1	0001);	2 = 82°	%			
Test for overall effect: Z =	2.27 (P	= 0.02	)							
1.3.2 CAL 3 months AL <	<7 mm									
Chitsazi et al. (M) 2014	1.29	0.62	24	0.75	0.65	24	7.8%	0.84 [0.24, 1.43]	2014	
Moreira et al. (M) 2014	1.53	0.59	20	1.58	0.63	20	7.7%	-0.08 [-0.70, 0.54]	2014	
Subtotal (95% CI)			44			44	15.5%	0.38 [-0.52, 1.28]		-
Heterogeneity: Tau <sup>2</sup> = 0.3	32; Chi <sup>2</sup> =	4.39,	df = 1 (	P = 0.04	4);   <sup>2</sup> =	77%				
Test for overall effect: Z =	0.84 (P	= 0.40	)							
1.3.3 CAL 3 months AL >	•7 mm									
Oliveira et al. (S) 2007	1.19	1.98	10	1.52	2.53	10	6.7%	-0.14 [-1.02, 0.74]	2007	
Moreira et al. (S) 2014	2.77	0.5	20	1.75	0.72	20	7.3%	1.61 [0.89, 2.34]	2014	
Annaji et al. (S) 2016	1.3	0.39	15	0.28	0.36	15	6.1%	2.64 [1.63, 3.66]	2016	
Borekci et al. (S) 2018	0.62	0.96	12	0.59	0.94	12	7.0%	0.03 [-0.77, 0.83]	2018	
Anderea et al. (S) 2018	2.5	0.99	18	2	0.67	18	7.5%	0.58 [-0.09, 1.25]	2018	
Subtotal (95% CI)			75			75	34.5%	0.92 [0.01, 1.84]		-
Heterogeneity: Tau <sup>2</sup> = 0.9	91; Chi <sup>2</sup> =	= 25.85	5, df = 4	(P < 0.1	0001);	I <sup>2</sup> = 85	%			
Test for overall effect: Z =	1.98 (P	= 0.05	)							
Total (95% CI)			238			238	100.0%	0.75 [0.31, 1.19]		•
Heterogeneity Tau <sup>2</sup> = 0.4	5' Chi <sup>2</sup> -	65 64	df = 1	3 (P < 0	0000	1): 12 = 1	80%			+
Test for overall effect: 7 =	3 34 (P	= 0.00	08)							-4 -2 0 2 4
	+ (i	0.00	/							SRP + PD1 SRP alone

**FIGURE 4.** Forest plot of CAL gain at 3 months follow-up between PDT + SRP and SRP alone groups. SRP: Scaling Root Planning, PDT: Photodynamic therapy, CAL: Clinical Attachment Loss.

Study or Subgroup Mean SD Total Mean SD Total Weight IV, Random, 95% CI Year IV, Random, 95% CI	
2.1.1 PD 3 months Total	
Oliveira et al. (8) 2007 1.43 1.25 10 0.94 1.39 10 4.8% 0.36 [-0.53, 1.24] 2007	
Anwaileretal. (M) 2012 1.1 0.46 17 1.8 0.42 18 5.1% -1.56 -2.32 -0.79 2012	
Moreira et al. (3) 2014 4 0.58 20 2.56 0.55 20 4.9% 2.50 (1.65, 3.34) 2014	
Moreira et al. (M) 2014 2.41 0.25 20 2.15 0.34 20 5.3% 0.85 (0.20, 1.50) 2014	
Chitsazi et al. (M) 2014 1.5 0.58 24 0.91 0.48 24 5.4% 1.09 (0.48, 1.70) 2014	
Annaji etal. (S) 2016 0.6 0.3 15 0.29 0.15 15 5.0% 1.27 [0.48, 2.07] 2016	
Anderea et al. (S) 2018 2.8 0.71 18 2.1 0.67 18 5.2% 0.99 (0.29, 1.69) 2018	
Borekci et al. (S) 2018 1.1 0.44 12 0.98 0.43 12 5.0% 0.27 [-0.54, 1.07] 2018	
Al-Khuriefetal.(S) 2019 2.1 1.6 9 1.69 1.16 8 4.7% 0.28 -0.68 1.23 2019	
Al-Khuriefetal.(M) 2019 2.2 0.55 9 1.89 0.64 8 4.6% 0.50 (-0.48, 1.47) 2019	
Subtotal (95% CI) 154 153 50.0% 0.66 [0.03, 1.28]	
Heterogeneity: Tau <sup>2</sup> = 0.85; Chi <sup>2</sup> = 57.55, df = 9 (P < 0.00001); I <sup>2</sup> = 84%	
Test for overall effect: Z = 2.07 (P = 0.04)	
2.1.2 PD 3 months AL <7 mm	
Arwailer et al. (M) 2012 1.1 0.46 17 1.8 0.42 18 5.1% -1.56 [-2.32, -0.79] 2012	
Moreira et al. (M) 2014 2.41 0.25 20 2.15 0.34 20 5.3% 0.85 (0.20, 1.50) 2014	
Chitsazi et al. (M) 2014 1.5 0.58 24 0.91 0.48 24 5.4% 1.09 [0.48, 1.70] 2014	
Al-Khuriefetal.(M) 2019 2.2 0.55 9 1.89 0.64 8 4.6% 0.50 [-0.48, 1.47] 2019	
Subtotal (95% CI) 70 70 20.4% 0.23 [-0.96, 1.42]	
Heterogeneity: Tau <sup>2</sup> = 1.32; Chi <sup>2</sup> = 31.72, df = 3 (P ≺ 0.00001); I <sup>2</sup> = 91%	
Test for overall effect: Z = 0.38 (P = 0.70)	
24.2.00.2 minute AL 57 mm	
Oliveira et al. (S) 2007 1.43 1.25 10 0.94 1.39 10 4.8% 0.36 [-0.53, 1.24] 2007	
Moreira et al. (5) 2014 4 0.58 20 2.56 0.55 20 4.9% 2.50 (1.65, 3.34) 2014	
Annaji et al. (\$) 2016 0.6 0.3 15 0.29 0.15 15 5.0% 1.27 [0.48, 2.07] 2016	
Borekci et al. (S) 2018 1.1 0.44 12 0.98 0.43 12 5.0% 0.27 (-0.54, 1.07) 2018	
Anderea et al. (5) 2018 2.8 0.71 18 2.1 0.67 18 5.2% 0.99 [0.29, 1.69] 2018	
Al-Khunet et al.(5) 2019 2.1 1.6 9 1.69 1.16 8 4.7% U.28 FU.68, 1.23 2019	
Sublocal (95% CI) 84 85 29.0% 0.95 [0.28, 1.02]	
Heterogenerity: 1au*= 0.52; Chr = 19.88; dt = 5 (P = 0.001); F = 75%	
Test for overall effect: $Z = 2.78$ (P = 0.005)	
Total (95% CI) 308 306 100.0% 0.66 [0.23, 1.09]	
Heterogeneity: Tau <sup>2</sup> = 0.79: Chi <sup>2</sup> = 115.11. df = 19 (P < 0.00001): I <sup>2</sup> = 83%	+
Test for overall effect $Z = 3.01 (P = 0.003)$	4
Test for subgroup differences: Chi <sup>2</sup> = 1.15. df = 2 (P = 0.56), I <sup>2</sup> = 0% SRP or SRP+AB SRP+PDT	

FIGURE 5. Forest plot of PD reduction at 3 months follow-up between PDT + SRP and SRP + AB or SRP alone. SRP: Scaling Root Planning, PDT: Photodynamic therapy, AB: antibiotics



**FIGURE 6.** Forest plot of BOP mean reduction at 3 months follow-up between PDT + SRP and SRP + AB groups. SRP: Scaling Root Planning, PDT: Photodynamic therapy, BOP: Bleeding on probing, AB: antibiotics



**FIGURE 7.** Forest plots based on sensitivity analysis showing the overall CAL gain (A) and PPD reduction (B) at 3 months without outlier studies. SRP: Scaling Root Planning, PDT: Photodynamic therapy, CAL: Clinical Attachment Loss, AB: antibiotics

#### Sensitivity analysis

A sensitivity analysis was conducted due to the noteworthy heterogeneity arising from outlier studies [21,23,35,36]. This analysis was shown only for the 3-month follow-up due to unavailability of data at 6 months in the included studies. The residual studies [10,20,22,25,26] were subjected to a sensitivity analysis which, in terms of CAL gain, disclosed statistically significant reduction (MD = 0.51 95% CI = [0.28, 0.73]; Z = 4.43 [p < 0.00001]) with low heterogeneity (T2 = 0.00; X2 = 10.35 [p = 0.5]; I2 = 0%) (Figure 7A). Improvement in PPD reduction was revealed statistically significant reduction after omitting outlier studies (MD = 0.69 95% CI = [0.46, 0.91]; Z = 5.92 [p = 0.56]) with no evident heterogeneity (T2 = 0.00; X2 = 9.72 (p < 0.00001); I2 = 0%) (Figure 7B).



FIGURE 8. Forest plot and funnel plots for CAL gain adjusted with Trim and Fill method. Circles indicate included studies (Stata Software). CAL: Clinical attachment loss

### Publication bias

The funnel plot of attachment gain using STATA version 16 (STATA Co., College Station, TX, USA) indicated the absence of asymmetry in the included studies (Figure 8). No asymmetry was noted when this analysis was conducted on studies that only performed SRP alone for the control group (Appendix S4). Assessment of this parameter by the Trim and Fill analysis revealed no missing study in the CAL > 7 mm group. However, in CAL < 7 mm group, one study was missed due to asymmetry (Appendices S5 and S6). Thus, the difference between the estimation of the original and adjusted effect size based on the Trim and Fill method was not significant in CAL > 7 mm group.

## DISCUSSION

The studies included in this meta-analysis evaluated the effect of aPDT as adjunctive therapy with SRP or SRP + AMX/MET on Stages II-IV Grade C molar-incisor pattern periodontitis (AgP) with CAL < and > 7 mm. In the current classification (2017), the diagnosis of periodontitis was defined in three steps: A: Staging represents severity and complexity of management. B: Extent and distribution, and C: Grading that represents evidence of risk of rapid progression and anticipated treatment response. Thus, Stages II-IV comprises patients who are diagnosed with moderate and severe (with potential for loss of the dentition) periodontitis. The rapid rate of progression represents Grade C and the molar-incisor pattern shows the distribution of the disease. The hypothesis of this study was that aPDT as adjunctive therapy in patients with CAL > 7 mm would bring about significant results, compared with those with CAL < 7 mm. However, further clinical, microbiologic, and immunological studies are required on the efficacy of aPDT in the different stages of this disease with a similar standard methodology. AgP is a relatively common inflammatory disease which can lead to early tooth loss due to CAL and extensive bone loss [45]. Antibiotic therapy and aPDT are the most commonly used non-surgical adjunctive treatments that are performed aiming to eliminate the microorganisms in hard-to-reach areas and those penetrating into the soft tissue [6,7,46]. To date, AMX/MET has been the most commonly used and most effective antibiotic regimen for AgP [47,48]. The common complications of antibiotic therapy such as the development of bacterial resistance are increasing due to widespread and negligent use of antibiotics and the consequent elimination of normal microflora. This has resulted in the application of aPDT due to its antimicrobial effects [22,23].

Several *in vitro, in vivo* [26,49], and animal [50] studies have shown the significant effect of aPDT with certain photosensitizers and laser energies on anaerobic microorganisms such as *Porphyromonas gingivalis* and *Aggregatibacter actinomycetemcomitans*. *P. gingivalis* is known to produce a repertoire of virulence factors that can penetrate the gingivae and cause periodontal tissue destruction directly or indirectly, by stimulation of inflammation [12]. It has also been seen that decreases in these bacterial counts are consistent with improvement of CAL gain and PD reduction [21], which are the dominant microbial species in dental plaque of patients with AgP. These microorganisms disintegrate the external membrane proteins [51,52] and produce many virulence factors that can directly or indirectly lead to the destruction of periodontal tissues by regulating host inflammatory responses [53]. Review studies and meta-analyses have shown the positive effects of aPDT on microorganisms [24,28,54-57].

With respect to the treatment outcome, all studies included in this review showed that aPDT was effective for the improvement of CAL gain and PD reduction in AgP patients; among which, only two studies reported a significant reduction in PPD and CAL parameters compared with the control group [21,23]. Two studies reported the optimal efficacy of aPDT only in deep pockets [20,23]. In the present study, aPDT along with SRP was significantly superior to the control group (SRP alone and SRP + AMX/MET) only in cases with CAL > 7 mm after 3 months. The results showed that aPDT plus SRP caused no significant improvement in clinical parameters in the short term in cases with CAL < 7 mm. In an assessment of oral hygiene instruction practiced in studies, only three out of eight studies [10,20,23] emphasized oral hygiene programs and home care instruction before mechanical treatments. Furthermore, complete debridement varied from conduction of SRP under local anesthesia [10,20,25] to debridement with ultrasonic and hand instruments in several sessions, and its continuation or discontinuation throughout the study can cause bias. Moreover, in RCTs with a control group of SRP + AMX/MET, high heterogeneity was noted due to high variation in the dosage of antibiotics (375-500 mg AMX and 250-500 mg MET). Such a high heterogeneity was also noted in the type of photosensitizer used such that phenothiazine chloride was used in five studies [10,20,23,35,36], while the remaining four studies used toluidine blue or methylene blue [21,22,25,26]. Excess photosensitizer was removed from the pockets with saline, water, or air jet after 1 [10,20,23,25,26] or 3 [22,36] minutes. Only one study [20] reported the concentration of photosensitizer used (10 mg). Thus, although the application of aPDT with 10 mg toluidine blue and methylene blue has been reported to be 100% effective in the elimination of A. actinomycetemcomitans in vitro [58], since the concentration of residual photosensitizer after rinsing the pocket with different techniques is not known, the concentration of reactive oxygen species for the elimination of pathogens involved in AgP cannot be assessed. Furthermore, the energy used per square millimeter varied in different studies. Five studies were not report this information [10,21,26,35,36]. In two studies, fluency per site was reported at 2.49 J/cm<sup>2</sup> [20,23]. Although, two studies used different fluency per site (20 [22] and 129 [25] J/cm<sup>2</sup>) in their studies.

Another reason responsible for high heterogeneity is the high variation in the frequency of application of aPDT with variable intervals. aPDT is recommended to be repeated over several sessions because it has been shown that SRP has a short-term effect, and recolonization of pocket occurs after 3 weeks [59]. Thus, aPDT should be preferably repeated for several sessions [54] to prevent pocket recolonization. It should be noted that the majority of studies included in this meta-analysis did not report the degree of improvement in clinical parameters separately after each treatment session. Only one study [21] compared the treatment results after the first and fourth treatment sessions. Furthermore, the three studies [20,21,23] that performed four sessions of PDT reported controversial results; however, they all reported maximum efficacy of aPDT in deep pockets. One study [20] reported that aPDT had no advantage over AMX/MET in the improvement of clinical parameters. Moreover, improvement of clinical parameters was not reported in different levels of CAL with specific and standardized control groups in the included studies. As a result, due to the high heterogeneity, sensitivity analysis was performed and the outline studies in visual inspection of forest plot analysis were omitted until low heterogeneity was achieved. This sensitivity analysis shows a significant difference in the CAL and PPD parameters of the PDT + SRP application versus SRP alone or with AMX/MET (Figure 7). Thus, RCTs with the same reproducible methodology are required on different levels of CAL with longer follow-ups to find the most effective treatment based on the type and number of plaque microorganisms. In general, high heterogeneity in methodologies such as plaque control methods, oral hygiene instructions provided to patients, technique and frequency of SRP sessions, laser parameters, output energy per surface unit (J/cm<sup>2</sup>), frequency of aPDT sessions, and type of photosensitizer in RCTs also cause bias and prevent achieving reliable results. Moreover, a recent study [60] has identified that certain wavelengths should be used with blue photosensitizers, and there is no photodynamic reaction at wavelengths above 800 nm (infrared) with the blue type of PS (toluidine blue and methylene blue). Hence, blue photosensitizers are used just with 635-660 nm wavelengths. Therefore, the RCTs that have used wavelengths above 800 nm with blue PS can cause bias in the systematic review and meta-analysis. Due to this, Annanji et al. (2016) study, which treated the patients with aPDT (wavelength 810 nm, PS: toluidine blue), was omitted in sensitivity analysis and the outcome shows a

significant difference in the application of PDT in terms of CAL parameter.

However, standardized treatments customized based on disease severity can estimate the necessity of application of this treatment modality and prevent its unnecessary prescription.

Assessment of attachment gain and PD reduction can help determine the necessity of conducting of aPDT, and a comparison between the effect sizes of different meta-analyses can greatly aid in designing a successful treatment plan.

The effect of aPDT versus SRP alone (as the control group) on AgP is important in terms of the effect size of attachment gain and PD reduction in meta-analyses, as shown in Figure 9A. Accordingly, the present meta-analysis indicated greater improvement of clinical parameters following PDT compared with other meta-analyses. Furthermore, a parallel assessment of meta-analyses on clinical parameters in CP patients revealed that despite the differences in the results of analyses (Figure 9B), better performance of aPDT was noted in CP compared with AgP (Figure 9B). The reason appears to be the greater presence of local factors such as calculus and dental plaque in CP, which are the main causes of the development of CP [61] and can be well eliminated by mechanical treatments. In other words, it may be stated that mechanical treatments in AgP cannot easily and completely remove the microorganisms and lead to acceptable recovery due to the presence of numerous risk factors, extensive CAL, and penetration of invading bacteria into deep tissues. Thus, aPDT causes greater improvement in AgP patients due to its antibacterial activity against the causative microorganisms lodged in deep tissues.



**FIGURE 9.** Effect size comparison of different meta-analysis studies in (A): CP patients (PDT+SRP vs. SRP) and (B) AgP patient (PDT + SRP vs. SRP alone).PD: Probing Depth, CAL: Clinical Attachment Loss, PDT: Photodynamic therapy, Agp: Aggressive periodontitis, SRP: Scaling Root Planning.

In some meta-analyses, treatment with AMX/MET was performed combined with SRP for the control group, as shown in Figure 10. The results indicated that regarding the effect size of attachment gain, aPDT + SRP caused a greater improvement by 50-90% compared with SRP + AMX/MET in the present study compared with other meta-analyses. This improvement can be due to a higher number of more recent studies included in the present meta-analysis. Furthermore, in the majority of studies, the level of attachment gain and PD reduction in the aPDT group was comparable to those in treatment with AMX/MET except for the study by Souza et al. (2021) [28] that showed that antibiotic therapy with AMX/MET was more successful than aPDT.

Although the present results were generally in line with the findings of recently published review articles [28,54] regarding the positive effect of PDT on AgP versus SRP or AMX/MET as adjunctive treatments, a more precise analysis of the effect size of attachment gain in the SRP alone and SRP + AMX/MET control groups in meta-analyses indicated 80% and 60% efficacy for aPDT, respectively, only in CAL > 7 mm. Furthermore, the level of improvement caused by aPDT in cases with CAL > 7 mm was almost the same in both control groups. In cases with CAL < 7 mm, AMX/MET did not cause a significant improvement in this parameter compared with SRP alone. In other words, aPDT is an effective treatment for cases of AgP with CAL > 7 mm compared with mechanical



**FIGURE 10.** Effect size comparison of different meta-analysis studies in AgP patients (PDT + SRP vs. SRP + AMX/MET). PD: Probing Depth, CAL: Clinical Attachment Loss, PDT: Photodynamic therapy, AMX/MET: Amoxicillin/Metronidazole, SRP: Scaling Root Planning.



**FIGURE 11.** Effect size comparison of CAL gain of AL> 7 mm and AL < 7 mm with different control groups. CAL: Clinical Attachment Loss, AL: Attachment Loss, AB: Antibiotic, SRP: Scaling Root Planning, PDT: Photodynamic therapy

treatment alone (Figure 11). Furthermore, since AMX/MET is more effective in cases with extensive CAL and deep pockets, the greatest improvement and microorganism reduction occur in cases with CAL > 7 mm.

Since the effect of different confounding factors was not adjusted, and different grades of disease were not evaluated in this study, the results of the analyses are not 100% reliable. However, it should be kept in mind that adjunctive treatments should be adopted only in a severe form of the disease for the elimination of microorganisms in hard-to-reach areas. Furthermore, considering the possible side effects such as eye injury in case of not correctly using protective eyeglasses, thermogenesis, and periodontal tissue injury due to the use of chemicals in effective concentrations [17], negligent use of such modalities in mild cases should be avoided due to the absence of conclusive evidence.

This study had some limitations such as the small number, and high heterogeneity of the included studies such that in qualitative analysis, only two studies had a low risk of bias. Furthermore, due to the limitations of RCTs in the assessment of different levels of CAL, the mean attachment loss reported in studies was used to categorize disease severity based on CAL < 7 mm and > 7 mm.

## CONCLUSION

Analysis of included studies indicated a significant difference in clinical attachment gain in patients with CAL > 7 mm between the aPDT group and the SRP alone and SRP + AMX/MET control groups. However, this difference was not significant in patients with CAL < 7 mm.

Despite the limitations within this meta-analysis, the aPDT was suggested as adjunctive therapy in the treatment of Stages II-IV, Grade C molar-incisor pattern periodontitis with CAL > 7 mm, although improvement of clinical parameters in the patients with CAL < 7 mm remains debatable.

## REFERENCES

- Armitage GC, Cullinan MP. Comparison of the clinical features of chronic and aggressive periodontitis. Periodontol 2000 2010;53:12-27.
  - https://doi.org/10.1111/j.1600-0757.2010.00353.x
- [2] Armitage GC. Development of a classification system for periodontal diseases and conditions. Northwest Dent 2000;79(6):31-5.
- [3] Caton JG, Armitage G, Berglundh T, Chapple IL, Jepsen S, Kornman KS, et al. A new classification scheme for periodontal and peri-implant diseases and conditions-Introduction and key changes from the 1999 classification. J Clin Periodontol 2018;45:S1-8. https://doi.org/10.1111/jcpe.12935.
- [4] der Velden UV. What exactly distinguishes aggressive from chronic periodontitis: Is it mainly a difference in the degree of bacterial invasiveness? Periodontol 2000 2017;75(1):24-44 https://doi.org/10.1111/prd.12202
- [5] Yek EC, Cintan S, Topcuoglu N, Kulekci G, Issever H, Kantarci A.

Efficacy of amoxicillin and metronidazole combination for the management of generalized aggressive periodontitis. J Periodontol 2010;81(7):964-74.

https://doi.org/10.1902/jop.2010.090522

[6] Quirynen M, De Soete M, Dierickx K, Steenberghe DV. The intraoral translocation of periodontopathogens jeopardises the outcome of periodontal therapy: A review of the literature. J Clin Periodontol 2001;28(6):499-507.

https://doi.org/10.1034/j.1600-051x.2001.028006499.x

- [7] Rateitschak-Plüss EM, Schwarz JP, Guggenheim R, Duggelin M, Rateitschak KH. Non-surgical periodontal treatment: Where are the limits? An SEM study. J Clin Periodontol 1992;19(4):240-4. https://doi.org/10.1111/j.1600-051x.1992.tb00460.x
- [8] Rabelo CC, Feres M, Gonçalves C, Figueiredo LC, Faveri M, Tu YK, et al. Systemic antibiotics in the treatment of aggressive periodontitis. A systematic review and a bayesian network meta-analysis. J Clin Periodontol 2015;42(7):647-57. https://doi.org/10.1111/jcpe.12427
- [9] Azarpazhooh A, Shah PS, Tenenbaum HC, Goldberg MB. The effect of photodynamic therapy for periodontitis: A systematic review and meta-analysis. J Periodontol 2010;81(1):4-14. https://doi.org/10.1902/jop.2009.090285
- [10] de Oliveira RR, Schwartz-Filho HO, Novaes AB Jr., Taba MJ Jr. Antimicrobial photodynamic therapy in the non-surgical treatment of aggressive periodontitis: A preliminary randomized controlled clinical study. J Periodontol 2007;78(6):965-73. https://doi.org/10.1902/jop.2007.060494
- [11] Fernandes LA, De Almeida JM, Theodoro LH, Bosco AF, Nagata MJ, Martins TM, et al. Treatment of experimental periodontal disease by photodynamic therapy in immunosuppressed rats. J Clin Periodontol 2009;36(3):219-28. https://doi.org/10.1111/j.1600-051X.2008.01355.x
- [12] Hamblin MR, Hasan T. Photodynamic therapy: A new antimicrobial approach to infectious disease? Photochem Photobiol Sci 2004;3(5):436-50.

https://doi.org/10.1039/b311900a

- [13] Tegos GP, Demidova TN, Arcila-Lopez D, Lee H, Wharton T, Gali H, et al. Cationic fullerenes are effective and selective antimicrobial photosensitizers. Chem Biol 2005;12(10):1127-35. https://doi.org/10.1016/j.chembiol.2005.08.014
- [14] Mohr H, Lambrecht B, Selz A. Photodynamic virus inactivation of blood components. Immunol Invest 1995;24(1-2):73-85. https://doi.org/10.3109/08820139509062763
- [15] Wainwright M, Maisch T, Nonell S, Plaetzer K, Almeida A, Tegos GP, et al. Photoantimicrobials-are we afraid of the light? Lancet Infect Dis 2017;17(2):e49-55.

https://doi.org/10.1016/s1473-3099(16)30268-7

[16] Kornman KS, Page RC, Tonetti MS. The host response to the microbial challenge in periodontitis: Assembling the players. Periodontol 2000 1997;14:33-53.

https://doi.org/10.1111/j.1600-0757.1997.tb00191.x

- [17] Rajesh S, Koshi E, Philip K, Mohan A. Antimicrobial photodynamic therapy: An overview. J Indian Soc Periodontol 2011;15(4):323-7. https://doi.org/10.4103/0972-124X.92563
- [18] Socransky SS. Microbiology of periodontal disease present status and future considerations. J Periodontol 1977;48(9):497-504. https://doi.org/10.1902/jop.1977.48.9.497
- [19] Hajishengallis G, Darveau RP, Curtis MA. The keystone-pathogen hypothesis. Nat Rev Microbiol 2012;10(10):717-25. https://doi.org/10.1038/nrmicro2873
- [20] Al-Khureif AA, Mohamed BA, Siddiqui AZ, Khan AA, Divakar DD. Repeated application of photodynamic and antibiotic therapy as an adjunct to root surface debridement in patients with grade C and stage III or IV aggressive periodontitis. Photodiagnosis Photodyn Ther 2020;29:101610.

https://doi.org/10.1016/j.pdpdt.2019.101610

[21] Annaji S, Sarkar I, Rajan P, Pai J, Malagi S, Bharmappa R, et al. Efficacy of photodynamic therapy and lasers as an adjunct to scaling and root planing in the treatment of aggressive periodontitis a clinical and microbiologic short term study. J Clin Diagn Res 2016;10(2):ZC08-12.

https://doi.org/10.7860/jcdr/2016/13844.7165

- [22] Borekci T, Meseli SE, Noyan U, Kuru BE, Kuru L. Efficacy of adjunctive photodynamic therapy in the treatment of generalized aggressive periodontitis: A randomized controlled clinical trial. Lasers Surg Med 2019;51(2):167-75. https://doi.org/10.1002/lsm.23010
- [23] Moreira AL, Novaes AB Jr., Grisi MF, Taba M Jr., Souza SL, Palioto DB, et al. Antimicrobial photodynamic therapy as an adjunct to non-surgical treatment of aggressive periodontitis: A split-mouth randomized controlled trial. J Periodontol 2015;86(3):376-86. https://doi.org/10.1902/jop.2014.140392
- [24] Souza E, Medeiros AC, Gurgel BC, Sarmento C. Antimicrobial photodynamic therapy in the treatment of aggressive periodontitis: A systematic review and meta-analysis. Lasers Med Sci 2016;31(1):187-96.

https://doi.org/10.1007/s10103-015-1836-0

[25] Andere NM, Santos NC, Araujo CF, Mathias IF, Rossato A, de Marco AC, et al. Evaluation of the local effect of nonsurgical periodontal treatment with and without systemic antibiotic and photodynamic therapy in generalized aggressive periodontitis. A randomized clinical trial. Photodiagnosis Photodyn Ther 2018;24:115-20.

https://doi.org/10.1016/j.pdpdt.2018.09.002

[26] Chitsazi MT, Shirmohammadi A, Pourabbas R, Abolfazli N, Farhoudi I, Azar BD, et al. Clinical and microbiological effects of photodynamic therapy associated with non-surgical treatment in aggressive periodontitis. J Dent Res Dent Clin Dent Prospects 2014;8(3):153-9.

https://doi.org/10.15171/joddd.2015.003

- [27] Akram Z. How effective is adjunctive antimicrobial photodynamic therapy in treating deep periodontal pockets in periodontal disease? A systematic review. J Investig Clin Dent 2018;9(4):e12345. https://doi.org/10.1111/jicd.12345
- [28] Souza EQ, da Rocha TE, Toro LF, Guiati IZ, Ervolino E, Garcia VG, et al. Antimicrobial photodynamic therapy compared to systemic antibiotic therapy in non-surgical treatment of periodontitis: Systematic review and meta-analysis. Photodiagnosis Photodyn Ther 2020;31:101808.

https://doi.org/10.1016/j.pdpdt.2020.101808

[29] Akram Z, Raffat MA, Shafqat S, Mirza S, Ikram S. Clinical efficacy of photodynamic therapy as an adjunct to scaling and root planing in the treatment of chronic periodontitis among cigarette smokers: A systematic review and meta-analysis. Photodiagnosis Photodyn Ther 2019;26:334-41.

https://doi.org/10.1016/j.pdpdt.2019.04.027

- [30] McHugh ML. Interrater reliability: The kappa statistic. Biochem Med (Zagreb) 2012;22(3):276-82. https://doi.org/10.11613/bm.2012.031
- [31] Chapple IL, Jepsen S. Response by the workgroup co-chairs. J Clin Periodontol 2021;48(4):555-6. https://doi.org/10.1111/jcpe.13425
- [32] Dalvi S, Benedicenti S, Hanna R. Is antimicrobial photodynamic therapy an effective treatment modality for aggressive periodontitis? A systematic review of *in vivo* human randomized controlled clinical trials. Photodiagnosis Photodyn Ther 2021;34:102314. https://doi.org/10.1016/j.pdpdt.2021.102314
- [33] Su X, Zhuang D, Zhang Y, Lv H, Wang Y, Luan X, et al. Influence of photodynamic therapy on the periodontitis-induced bone resorption in rat. Lasers Med Sci 2021;36(3):675-80. https://doi.org/10.1007/s10103-020-03126-8
- [34] Zhao P, Song X, Wang Q, Zhang P, Nie L, Ding Y, et al. Effect of adjunctive diode laser in the non-surgical periodontal treatment in patients with diabetes mellitus: A systematic review and meta-analysis. Lasers Med Sci 2021;36(5):939-50. https://doi.org/10.1007/S10103-020-03208-7
- [35] Arweiler NB, Pietruska M, Pietruski J, Skurska A, Dolińska E, Heumann C, et al. Six-month results following treatment of aggressive periodontitis with antimicrobial photodynamic therapy or amoxicillin and metronidazole. Clin Oral Investig

2014;18(9):2129-35.

https://doi.org/10.1007/s00784-014-1193-6

- [36] Arweiler NB, Pietruska M, Skurska A, Dolińska E, Pietruski JK, Bläs M, et al. Nonsurgical treatment of aggressive periodontitis with photodynamic therapy or systemic antibiotics. Three-month results of a randomized, prospective, controlled clinical study. Schweiz Monatsschr Zahnmed 2013;123(6):532-44. https://doi.org/10.1007/s00784-014-1193-6
- [37] Muzaheed M, Acharya S, Hakami AR, Allemailem KS, Alqahtani K, Al Saffan A, et al. Effectiveness of single versus multiple sessions of photodynamic therapy as adjunct to scaling and root planing on periodontopathogenic bacteria in patients with periodontitis. Photodiagnosis Photodyn Ther 2020;32:102035. https://doi.org/10.1016/j.pdpdt.2020.102035
- [38] Pulikkotil S, Toh C, Mohandas K, Leong KJ. Effect of photodynamic therapy adjunct to scaling and root planing in periodontitis patients: A randomized clinical trial. Aust Dent J 2016;61(4):440-5. https://doi.org/10.1111/adj.12409
- [39] Sgolastra F, Petrucci A, Severino M, Graziani F, Gatto R, Monaco A. Adjunctive photodynamic therapy to non-surgical treatment of chronic periodontitis: A systematic review and meta-analysis. J Clin Periodontol 2013;40(5):514-26. https://doi.org/10.1111/jcpe.12094
- [40] Theodoro LH, Silva SP, Pires JR, Soares GH, Pontes AE, Zuza EP, et al. Clinical and microbiological effects of photodynamic therapy associated with nonsurgical periodontal treatment. A 6-month follow-up. Lasers Med Sci 2012;27(4):687-93. https://doi.org/10.1007/s10103-011-0942-x
- [41] Al-Hamoudi N, Mokeem S, Shafqat SS, Vohra F, Abduljabbar T, Therapy P. Effectiveness of antimicrobial photodynamic therapy as an adjunct to open flap debridement in patients with aggressive periodontitis. Photodiagnosis Photodyn Ther 2021;33:102075. https://doi.org/10.1016/j.pdpdt.2020.102075
- [42] Skurska A, Dolinska E, Pietruska M, Pietruski JK, Dymicka V, Kemona H, et al. Effect of nonsurgical periodontal treatment in conjunction with either systemic administration of amoxicillin and metronidazole or additional photodynamic therapy on the concentration of matrix metalloproteinases 8 and 9 in gingival crevicular fluid in patients with aggressive periodontitis. BMC Oral Health 2015;15(1):1-5.

https://doi.org/10.1186/s12903-015-0048-0

[43] Takasaki AA, Aoki A, Mizutani K, Schwarz F, Sculean A, Wang C, et al. Application of antimicrobial photodynamic therapy in periodontal and peri-implant diseases. Periodontol 2000 2009;51(1):109-40.

https://doi.org/10.1111/j.1600-0757.2009.00302.x

- [44] Moher D, Schulz KF, Altman DG. The CONSORT statement: Revised recommendations for improving the quality of reports of parallel-group randomised trials. Lancet 2001;357(9263):1191-4. https://doi.org/10.1016/s0140-6736(00)04337-3
- [45] Dommisch H, Kebschull M. In: Kennedy JF, editor. Aggressive Periodontitis Newman and Carranza's Clinical Periodontology. 13th ed. Philadelphia, PA: Saunders, Elsevier Inc.; 2019. p. 352. https://doi.org/10.1080/07380577.2021.1983239
- [46] Adriaens PA, Edwards CA, De Boever JA, Loesche WJ. Ultrastructural observations on bacterial invasion in cementum and radicular dentin of periodontally diseased human teeth. J Periodontol 1988;59(8):493-503.

https://doi.org/10.1902/jop.1988.59.8.493

[47] Sgolastra F, Petrucci A, Gatto R, Monaco A. Effectiveness of systemic amoxicillin/metronidazole as an adjunctive therapy to full-mouth scaling and root planing in the treatment of aggressive periodontitis: A systematic review and meta-analysis. J Periodontol 2012;83(6):731-43.

https://doi.org/10.1902/jop.2011.110432

[48] Zandbergen D, Slot DE, Cobb CM, der Weijden FA. The clinical effect of scaling and root planing and the concomitant administration of systemic amoxicillin and metronidazole: A systematic review. J Periodontol 2013;84(3):332-51. https://doi.org/10.1902/jop.2012.120040

- [49] Matevski D, Weersink R, Tenenbaum HC, Wilson B, Ellen RP, Lépine G. Lethal photosensitization of periodontal pathogens by a red-filtered Xenon lamp in vitro. J Periodontal Res 2003;38(4):428-35. https://doi.org/10.1034/j.1600-0765.2003.00673.x
- [50] Kömerik N, Nakanishi H, MacRobert A, Henderson B, Speight P, Wilson M, et al. In vivo killing of Porphyromonas gingivalis by toluidine blue-mediated photosensitization in an animal model. Antimicrob Agents Chemother 2003;47(3):932-40. https://doi.org/10.1128/aac.47.3.932-940.2003
- [51] Bhatti M, MacRobert A, Meghji S, Henderson B, Wilson M. Effect of dosimetric and physiological factors on the lethal photosensitization of Porphyromonas gingivalis in vitro. Photochem Photobiol 1997;65(6):1026-31.

https://doi.org/10.1111/j.1751-1097.1997.tb07964.x

Bhatti M, MacRobert A, Meghji S, Henderson B, Wilson M. A study [52] of the uptake of toluidine blue O by Porphyromonas gingivalis and the mechanism of lethal photosensitization. Photochem Photobiol 1998;68(3):370-6.

https://doi.org/10.1111/j.1751-1097.1998.tb09694.x

[53] How KY, Song KP, Chan KG. Porphyromonas gingivalis: An overview of periodontopathic pathogen below the gum line. Front Microbiol 2016;7:53.

https://doi.org/10.3389/fmicb.2016.00053

[54] Dalvi S, Benedicenti S, Hanna R. Therapy P. Is antimicrobial photodynamic therapy an effective treatment modality for aggressive periodontitis? A systematic review of in vivo human randomized controlled clinical trials. Photodiagnosis Photodyn Ther 2021;34:102314.

https://doi.org/10.1016/j.pdpdt.2021.102314

- [55] Nuernberg MA, Miessi DM, Ivanaga CA, Olivo MB, Ervolino E, Garcia VG, et al. Influence of antimicrobial photodynamic therapy as an adjunctive to scaling and root planing on alveolar bone loss: A systematic review and meta-analysis of animal studies. Photodiagnosis Photodyn Ther 2019;25:354-63. https://doi.org/10.1016/j.pdpdt.2019.01.020
- [56] Vohra F, Akram Z, Safii SH, Vaithilingam RD, Ghanem A, Sergis K, et al. Role of antimicrobial photodynamic therapy in the treatment of aggressive periodontitis: A systematic review. Photodiagnosis Photodyn Ther 2016;13:139-47. https://doi.org/10.1016/j.pdpdt.2015.06.010
- Xue D, Zhao Y. Clinical effectiveness of adjunctive antimicro-[57] bial photodynamic therapy for residual pockets during supportive periodontal therapy: A systematic review and meta-analysis. Photodiagnosis Photodyn Ther 2017;17:127-33. https://doi.org/10.1016/j.pdpdt.2016.11.011
- [58] Valle LA, Lopes MM, Zangrando MS, Sant'Ana AC, Greghi SL, de Rezende ML, et al. Blue photosensitizers for aPDT eliminate aggregatibacter actinomycetemcomitans in the absence of light: An in vitro study. J Photochem Photobiol B 2019;194:56-60. https://doi.org/10.1016/j.jphotobiol.2019.03.005
- [59] Sbordone L, Ramaglia L, Gulletta E, Iacono V. Recolonization of the subgingival microflora after scaling and root planing in human periodontitis. J Periodontol 1990;61(9):579-84. https://doi.org/10.1902/jop.1990.61.9.579
- [60] Damante CA. Laser parameters in systematic reviews. J Clin Periodontol 2021;48(4):550-2.
- [61] Novak JM, Novak KF. Chronic periodontitis. In: Carranza's Clinical Periodontology. St. Louis: Elsevier, Saunders; 2011. p. 163.

#### **Related articles published in BJBMS**

- 1. Comparison of local infiltration and epidural analgesia for postoperative pain control in total knee arthroplasty and total hip arthroplasty: A systematic review and meta-analysis Huan Yan et al., BJBMS, 2016
- 2. The efficacy and safety of statin in combination with ezetimibe compared with double-dose statin in patients with high cardiovascular risk: A meta-analysis

Yunyun Zhu et al., BJBMS, 2020

3. Tranexamic acid is associated with decreased transfusion, hospital length of stay, and hospital cost in simultaneous bilateral total knee arthroplasty

Ryan DSouza et al., BJBMS, 2020

# SUPPLEMENTAL DATA

APPENDIX S1.	List o	of reasons	for	exclusion	of	articles	in	the
stage of full-tex	t asse	ssment						

0	
Excluded study	Reasons
Akram et al. [23]	Evaluated AgP and CP cases altogether
Muzaheed et al. [30]	Evaluated AgP and CP cases altogether
Pulikkotil et al. [31]	Evaluated AgP and CP cases altogether
Sgolastra et al. [32]	Only evaluated CP patients
Theodoro et al. [33]	Only evaluated CP patients
Al-Hamoudi et al. [34]	Not assessing the clinical parameters
Skurska et al. [35]	Having a control group not meeting the inclusion criteria
Takasaki et al. [36]	Being a review article

	SRI	P + PD	т	SRP o	r SRP+	AB		Std. Mean Difference		Std. Mean Difference
Study or Subgroup	Mean	SD	Total	Mean	SD	Total	Weight	IV, Random, 95% CI	Year	IV, Random, 95% CI
2.3.4 CAL 6 months Total										
Arwailer et al. (M) 2012	0.9	0.8	17	1.7	0.54	18	10.5%	-1.15 [-1.87, -0.43]	2012	
Arwailer et al. (S) 2012	2	0.94	17	3.8	0.81	18	10.1%	-2.01 [-2.84, -1.18]	2012	
Anderea et al. (S) 2018	2.4	0.88	18	2.3	0.67	18	10.7%	0.13 [-0.53, 0.78]	2018	
Al-Khurief et al.(M) 2019	2.69	0.89	9	2.59	1.05	8	9.7%	0.10 [-0.86, 1.05]	2019	
Al-Khurief et al.(S) 2019	3.78	1.1	9	2.18	0.73	8	9.1%	1.61 [0.47, 2.74]	2019	
Subtotal (95% CI)			70			70	50.0%	-0.31 [-1.39, 0.78]		-
Heterogeneity: Tau <sup>2</sup> = 1.33	; Chi² =	34.04	df = 4	(P < 0.00	0001); I	<sup>2</sup> = 88%	6			
Test for overall effect: Z = 0	).55 (P =	: 0.58)								
2.3.5 CAL 6 months AL >7	mm									
Arwailer et al. (S) 2012	2	0.94	17	3.8	0.81	18	10.1%	-2.01 [-2.84, -1.18]	2012	
Anderea et al. (S) 2018	2.4	0.88	18	2.3	0.67	18	10.7%	0.13 [-0.53, 0.78]	2018	
Al-Khurief et al.(S) 2019	3.78	1.1	9	2.18	0.73	8	9.1%	1.61 [0.47, 2.74]	2019	
Subtotal (95% CI)			44			44	29.8%	-0.12 [-1.99, 1.74]		
Heterogeneity: Tau <sup>2</sup> = 2.51	; Chi² =	28.76,	df = 2	(P < 0.00	0001);1	²= 93%	6			
Test for overall effect: $Z = 0$	).13 (P =	: 0.90)								
2.3.6 CAL 6 months AL <7	mm									
Arwailer et al. (M) 2012	0.9	0.8	17	1.7	0.54	18	10.5%	-1.15 [-1.87, -0.43]	2012	
Al-Khurief et al. (M) 2019	2.69	0.89	9	2.59	1.05		9.7%	0.10 (-0.86, 1.05)	2019	
Subtotal (95% CI)			26			26	20.2%	-0.57 [-1.79, 0.66]		-
Heterogeneity: Tau <sup>2</sup> = 0.60	: Chi <sup>2</sup> =	4.20. 0	df = 1 (F	P = 0.04)	$ ^{2} = 76$	6%				
Test for overall effect: Z = 0	).91 (P =	0.36)								
	•									
Total (95% CI)			140			140	100.0%	-0.31 [-1.03, 0.41]		
Heterogeneity: Tau <sup>2</sup> = 1.14	; Chi <sup>2</sup> =	68.09	df = 9	(P < 0.00	0001);1	<sup>2</sup> = 87%	6			
Test for overall effect: Z = 0	).85 (P =	0.40)								-4 -2 U 2 4
Test for subgroup differen	ces: Chi	<sup>2</sup> = 0.1	8. df = :	2 (P = 0.	91), l² =	= 0%				

**APPENDIX S2.** Forest plot of CAL gain at 6 months follow-up between PDT+SRP and SRP+ AB groups. SRP: Scaling Root Planning, PDT: Photodynamic therapy, CAL: Clinical Attachment Loss, AB: Antibiotics.

	SF	RP+PDT		SR	P alon	е		Std. Mean Difference		Std. Mean Difference
Study or Subgroup	Mean	SD	Total	Mean	SD	Total	Weight	IV, Random, 95% CI	Year	IV, Random, 95% Cl
1.1.1 PD 3 months Total										
Oliveira et al. (S) 2007	1.43	1.25	10	0.94	1.39	10	6.3%	0.36 [-0.53, 1.24]	2007	- <b>-</b>
Chitsazi et al. (M) 2014	1.5	0.58	24	0.91	0.48	24	8.2%	1.09 [0.48, 1.70]	2014	
Moreira et al. (M) 2014	2.41	0.255	20	2.15	0.34	20	7.9%	0.85 [0.20, 1.50]	2014	
Moreira et al. (S) 2014	4	0.58	20	2.56	0.55	20	6.5%	2.50 [1.65, 3.34]	2014	
Annaji et al. (S) 2016	0.6	0.3	15	0.29	0.15	15	6.9%	1.27 [0.48, 2.07]	2016	
Anderea et al. (S) 2018	2.8	0.71	18	2.1	0.67	18	7.5%	0.99 [0.29, 1.69]	2018	
Borekci et al. (S) 2018	1.1	0.44	12	0.98	0.43	12	6.8%	0.27 [-0.54, 1.07]	2018	
Subtotal (95% CI)			119			119	50.0%	1.04 [0.55, 1.53]		•
Heterogeneity: Tau <sup>2</sup> = 0.2	8; Chi <sup>z</sup> =	= 17.95,	df = 6 (	(P = 0.0)	06); I² =	= 67%				
Test for overall effect: Z =	4.19 (P	< 0.000	1)							
1.1.2 PD 3 months AL <7	mm									
Chitsazi et al. (M) 2014	1.5	0.58	24	0.91	0.48	24	8.2%	1.09 [0.48, 1.70]	2014	
Moreira et al. (M) 2014	2.41	0.255	20	2.15	0.34	20	7.9%	0.85 [0.20, 1.50]	2014	
Subtotal (95% CI)			44			44	16.1%	0.98 [0.53, 1.42]		•
Heterogeneity: Tau <sup>2</sup> = 0.0	0; Chi <sup>z</sup> =	= 0.28, d	lf = 1 (F	<sup>e</sup> = 0.59)	; <b> </b> ² = 0	%				
Test for overall effect: Z =	4.30 (P	< 0.000	1)							
1.1.3 PD 3 months AL >7	mm									
Oliveira et al. (S) 2007	1.43	1.25	10	0.94	1.39	10	6.3%	0.36 [-0.53, 1.24]	2007	
Moreira et al. (S) 2014	4	0.58	20	2.56	0.55	20	6.5%	2.50 [1.65, 3.34]	2014	
Annaji et al. (S) 2016	0.6	0.3	15	0.29	0.15	15	6.9%	1.27 [0.48, 2.07]	2016	
Borekci et al. (S) 2018	1.1	0.44	12	0.98	0.43	12	6.8%	0.27 [-0.54, 1.07]	2018	
Anderea et al. (S) 2018	2.8	0.71	18	2.1	0.67	18	7.5%	0.99 [0.29, 1.69]	2018	
Subtotal (95% CI)			75			75	33.9%	1.08 [0.32, 1.83]		-
Heterogeneity: Tau <sup>2</sup> = 0.5	7; Chi <b>²</b> =	= 17.56,	df = 4 (	(P = 0.0)	02); I² =	= 77%				
Test for overall effect: Z =	2.81 (P	= 0.005	)							
Total (05% CI)			220			220	100.0%	4 04 [0 74 4 27]		
Hatavananaitu Tav? 0.0	5. OH 3	25.00	238	(D - C -	0000	238	100.0%	1.04 [0.71, 1.37]		
Heterogeneity: 1 auf = 0.2	5; Chife	= 35.89,	$a_1 = 13$	(P = 0.1	0006);	r= 64	%			-4 -2 0 2 4
Test for overall effect: Z =	6.18 (P	< 0.000	01) 0			~~				SRP alone SRP+PDT
lest for subgroup differer	nces: Ch	nr*= 0.0	6, dt = 1	2 (P = 0.	97), P	= 0%				

**APPENDIX S3.** Forest plot of PD reduction at 3 months follow-up between PDT+SRP and SRP alone. SRP: Scaling Root Planning, PDT: Photodynamic therapy, AL: Attachment loss.



Random-effects REML model



STUDIES | HEDGES' G [95% CONF. Interval]

**OBSERVED | 0.**760 0.036 1.484

**OBSERVED + IMPUTED | 0.**760 0.036 1.484

**APPENDIX S4.** Forest plot of CAL gain, funnel plot, and Trim and Fill method at 3 months follow-up between PDT +SRP and SRP alone (total), SRP: Scaling Root Planning, PDT: Photodynamic therapy, CAL: Clinical attachment loss.



**APPENDIX S5.** Forest plot of CAL gain, funnel plot, and Trim and Fill method at 3 months follow-up between PDT +SRP and SRP alone groups in attachment loss <7 mm (Stata Software).







STUDIES | HEDGES' G [95% CONF. Interval]

OBSERVED | 0.857 0.515 1.199

**OBSERVED + IMPUTED | 0.**857 0.515 1.199

**APPENDIX S6.** Forest plot of CAL gain, funnel plot, and Trim and Fill method at 3 months follow-up between PDT + SRP and SRP alone groups in attachment loss >7 mm (Stata Software). SRP: Scaling Root Planning, PDT: Photodynamic therapy, CAL: Clinical attachment loss.